What This Means for Our Practice Seven additional Phase 3 trials are expected in 2026, evaluating retatrutide across obesity, type 2 diabetes, sleep apnea, chronic low back pain, and MASLD
Contact the experienced Chicago personal injury lawyers from TorHoerman Law for a free, no-obligation Chicago personal injury lawsuit case consultation today
You have high baseline BMI where 28.7% weight loss represents a clinically meaningful target
Triple agonist oral therapies remain investigational
Limited data exists for: Understudied Populations: Adults over 75 years (increased sensitivity to appetite suppression) Adolescents (ongoing development considerations) Individuals with BMI under 27 (insufficient safety data) Pregnant or lactating individuals (no safety data) Individuals with significant psychiatric conditions Gender Considerations: Research suggests some metabolic peptides may show differential effects between males and females, though data for cagrilintide and retatrutide specifically remains limited
Able C, Liao B, Saffati G, et al
